← All trials
NCT04173455
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2019
- Primary completion
- Sep 30, 2021
- Completion date
- Feb 28, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 46
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityReponsible party - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Hangzhou HeZheng Pharmaceutical Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.